Press Releases

Date	Title
7/2/13	Sarepta Therapeutics to Present Company Overview at the JMP Securities Healthcare Conference
6/19/13	Sarepta Therapeutics Announces Eteplirsen Demonstrates a Continued Benefit on Walking Test Through 84 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy
6/5/13	Sarepta Therapeutics to Present Company Overview at the Wells Fargo Securities 2013 Healthcare Conference
5/10/13	Sarepta Therapeutics to Present Company Overview at Upcoming Conferences
5/9/13	Sarepta Therapeutics Announces First Quarter 2013 Financial Results and Recent Corporate Developments
5/7/13	Sarepta Therapeutics Initiates Dosing in Phase I Multiple Ascending Dose Study of Drug for Treatment of Marburg Virus
4/26/13	Sarepta Therapeutics to Announce First Quarter 2013 Financial Results and Corporate Update on May 9, 2013
4/18/13	Sarepta Therapeutics to Present Company Overview at the Needham Annual Healthcare Conference
4/15/13	Sarepta Therapeutics Announces FDA Will Consider Accelerated Approval for Eteplirsen After Further Review of Data on Dystrophin and Clinical Outcomes
4/11/13	Sarepta Therapeutics and University of Western Australia Announce Exclusive Worldwide Licensing Agreement for Exon-Skipping Program in Duchenne Muscular Dystrophy

IR Menu